February 13, 2017
Fitch Even partner Kendrew H. Colton was quoted in an article published in this week’s issue of Chemical & Engineering News, a publication of the American Chemical Society.
The article, titled "Dispute Over the Legal Rights to an Anticancer Agent Continues," discusses the ongoing dispute between Scripps Research Institute California and Oncoceutics, Inc., a clinical-stage drug discovery and development company, involving the patent for an anticancer agent.
Ken has been practicing intellectual property law for over 30 years. His primary practice focus is counseling clients on a wide range of IP matters involving established and emerging chemical and biochemical technologies. Ken has been a member of the Chemical & Engineering News Advisory Board since 2012.
- Leveraging Separate IPR Counsel to Maximize Litigation SuccessFitch Even Webinar: November 18, 2021 Read more
IP Alert | USPTO Abused Discretion by Allowing Further Abuse by Ex Parte ReexaminationOctober 22, 2021
On September 29, in In re Vivint, Inc., the Federal Circuit clarified the interplay between petitions for IPR and a subsequent request for ex parte reexamination. Read more